Quarterly report (Form 10-Q)
Edwards Lifesciences 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
In October 2026, we received FDA approval for the PASCAL Precision System for tricuspid valve repair to support patients with symptomatic severe tricuspid regurgitation.